Opdivo in Combination with Yervo Demonstrates Improved Overall Survival for...
A Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or metastatic renal cell […] The post Opdivo in Combination with Yervo Demonstrates...
View ArticleOpdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma
Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or […] The post Opdivo Proves Superior to Yervoy for Adjuvant...
View ArticleImfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer
Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC). The novel immunotherapy checkpoint […] The post Imfinzi Improves Survival in Stage 3 Non Small Cell...
View ArticleKeytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line...
Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced […] The post Keytruda® Significantly Prolongs Survival Compared to...
View ArticleCheckpoint Inhibitors Improve Outcomes of Renal Cell Cancer
Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with […] The post Checkpoint Inhibitors Improve...
View ArticleFDA Approves Checkpoint Inhibitor Targeted Immunotherapy for Treatment of...
The U.S. Food and Drug Administration recently approved two precision cancer medicines for the treatment of colorectal cancer with a […] The post FDA Approves Checkpoint Inhibitor Targeted...
View ArticleFirst Line Combination Therapy Improves Progression-Free Survival In Advanced...
A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment […] The post First Line Combination...
View ArticleFDA Approves Opdivo for Adjuvant Treatment of Melanoma
CancerConnect News: The United States Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, Opdivo (nivolumab) for […] The post FDA Approves Opdivo for Adjuvant...
View ArticleNew Immunotherapy for Lung Cancer Shows Promise of Success
Novel combination of drugs is a huge step forward in cancer treatment In a groundbreaking development, results from a recent […] The post New Immunotherapy for Lung Cancer Shows Promise of Success...
View ArticleFDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer
CancerConnect News: The Food and Drug Administration granted approvals to Opdivo (nivolumab) and Yervoy (ipilimumab) in combination for the treatment […] The post FDA Approves Opdivo plus Yervoy...
View Article
